Ocular Therapeutix, Inc. announced that Regeneron has terminated the option and license agreement collaboration between the companies. The termination became effective August 5, 2021. The collaboration with Regeneron was initially formed in 2016 for the development and commercialization of products containing the Company's sustained-release hydrogel technology in combination with Regeneron's large molecule vascular endothelial growth factor (“VEGF”)-targeting compounds to address conditions of the eye.

Under a 2020 amendment, the Company and Regeneron's efforts have focused on research and development of an extended-delivery formulation of aflibercept to be delivered to the suprachoroidal space for the treatment of retinal diseases.